Vir Biotechnology, Inc. has reported positive topline results from its pivotal Phase 3 ECLIPSE 1 clinical trial, which evaluated a combination regimen for treating chronic hepatitis delta (CHD). The results indicate a significant response rate, potentially marking a breakthrough in treatment options for patients suffering from this challenging liver disease.

The ECLIPSE 1 trial focused on the investigational drugs elebsiran and tobevibart, administered monthly via subcutaneous injection. The trial met its primary endpoint, showing a 44% response rate in patients achieving undetectable hepatitis delta virus (HDV) RNA levels and normalization of alanine aminotransferase (ALT) at 48 weeks. In contrast, the delayed treatment group recorded a 0% response rate at the same point, with a p-value of less than 0.0001, underscoring the treatment's efficacy.

Background

Vir Biotechnology, Inc. is a publicly traded company on the Nasdaq under the ticker symbol VIR. The company specializes in developing innovative therapies for infectious diseases and other serious conditions, classified under the SIC code 2836, which pertains to biological products (no diagnostic substances). Recent filings include an 8-K on November 9, 2026, detailing the latest trial results.

What the Filing Says

According to the SEC filing, the company stated, "The trial's primary endpoint was met, with a 44% response rate in patients receiving elebsiran and tobevibart achieving undetectable virus... compared with 0% in the delayed treatment group at Week 12 (p<0.0001)." This statement highlights the significance of the findings and the potential implications for treatment protocols in CHD.

Impact

This development may significantly impact patients suffering from chronic hepatitis delta, offering them new hope through a potentially effective treatment regimen. Additionally, the results could influence the broader biological products industry, prompting competitors to evaluate their own treatment strategies and research directions.

What's Next

Vir Biotechnology plans to hold a virtual investor conference call on November 9, 2026, at 5:30 a.m. PT / 8:30 a.m. ET to discuss these results in detail. The company will also present further data from the ongoing Phase 2 SOLSTICE study, which complements the findings from the ECLIPSE 1 trial.

Details were not available in the SEC filing regarding any further actions or timelines following this announcement.